Acropolis Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Acropolis Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-469	Closed	-$209K	–	305
2025 Q3	$209K	Sell	469 -13	-3%	-$5.43K	0.01%	254
2025 Q2	$215K	Buy	482 +6	+1%	+$2.77K	0.01%	232
2025 Q1	$231K	Buy	476 +3	+0.6%	+$1.4K	0.01%	214
2024 Q4	$190K	Buy	473 +13	+3%	+$6.03K	0.01%	237
2024 Q3	$214K	Hold	460	–	–	0.01%	214
2024 Q2	$216K	Sell	460 -112	-20%	-$48.6K	0.01%	213
2024 Q1	$239K	Hold	572	–	–	0.02%	207
2023 Q4	$233K	Hold	572	–	–	0.02%	204
2023 Q3	$199K	Buy	+572	New	+$200K	0.02%	213

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Acropolis Investment Management's VRTX Position: Q4 2025 in Review

Acropolis Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 469 shares — an estimated $209K sold.

Acropolis Investment Management first reported a position in VRTX in Q3 2023 and held it in 9 quarters. The position peaked at $239K in Q1 2024. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Acropolis Investment Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Acropolis Investment Management sold 469 Vertex Pharmaceuticals shares in Q4 2025, an estimated $209K.
Acropolis Investment Management first reported a position in Vertex Pharmaceuticals in Q3 2023 and held it in 9 quarters.
Acropolis Investment Management's Vertex Pharmaceuticals position peaked at $239K in Q1 2024.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Acropolis Investment Management's 13F filing for Q4 2025, filed 14 Jan 2026.